Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 29Neoplasms 10Brain Neoplasms 6Neoplasm Metastasis 3Thyroid Neoplasms 2Thyroid Cancer, Papillary 2Skin Neoplasms 2Multiple Myeloma 2Hematologic Neoplasms 2Glioma 2Carcinoma, Non-Small-Cell Lung 2Thyroid Carcinoma, Anaplastic 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oligodendroglioma 1Nonseminomatous germ cell tumor 1Neurofibroma, Plexiform 1Neurocytoma 1Neuroblastoma 1Lymphoma 1Leukemia, Hairy Cell 1Histiocytosis, Langerhans-Cell 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Ganglioneuroma 1Ganglioglioma 1Fever 1Differentiated Thyroid Cancer (DTC) 1Colorectal Neoplasms 1Biliary Tract Neoplasms 1Astrocytoma 1

Interventions

trametinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Ameloblastoma × dabrafenib × Clear all
NCT02367859 2024-01-30

Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma

Stanford University

Phase 2 Completed
1 enrolled 5 charts

Ameloblastoma, Adamantinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡